GlassScriptPhysician profile
Adam Ross Schertz
NPI 1952798985
$2,529.62
in general payments reported to CMS, 2019-2025
15 companies · $613 in 2025
The $613 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $119 · 2024: $1,797 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,438 · Travel and Lodging: $1,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,438.03 |
| Travel and Lodging | $1,091.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,957.48 | 2024-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $169.97 | 2024-2025 | Nucala, Trelegy Ellipta |
| United Therapeutics Corporation | $51.40 | 2023-2024 | Tyvaso |
| Merck Sharp & Dohme LLC | $47.21 | 2023-2024 | |
| Insmed, INC. | $46.29 | 2025 | Arikayce |
| Amgen INC. | $46.27 | 2023-2025 | Tezspire |
| Mylan Specialty L.P. | $39.31 | 2024 | Yupelri |
| Baxter Healthcare | $28.04 | 2023 | Hillrom - Life 2000 Ventilation System |
| Astellas Pharma US INC | $25.90 | 2025 | Cresemba |
| Regeneron Healthcare Solutions, INC. | $24.89 | 2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.33 | 2025 | Jascayd |
| Electromed, INC. | $21.12 | 2023 | Smartvest |
| Avadel Cns Pharmaceuticals, LLC | $16.83 | 2025 | Lumryz |
| Lilly USA, LLC | $16.42 | 2025 | Zepbound, Mounjaro |
| Viatris Specialty LLC | $16.16 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Schertz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.